Plain-English translation of NCT06754644 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing whether a new medication called , given together with chemotherapy, works as well as Keytruda (an already-approved immunotherapy drug) also given with chemotherapy. The trial involves about 800 people with advanced lung cancer that has spread to other parts of the body. Researchers want to compare how well the new treatment works and how safe it is compared to the established option.
Immunotherapy has helped many people with advanced lung cancer live longer, but doctors are always looking for new options that might work better, work for more patients, or have fewer side effects. This trial will help determine whether this new medication is a good alternative to existing treatments.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to receive either the new medication or Keytruda, both given alongside chemotherapy. You will visit the clinic regularly for infusions (IV treatments), blood tests, and scans to monitor how well the treatment is working and check for side effects. The study will track your health and how you respond to treatment over time to compare the two approaches.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
China
Phase
Large-scale testing
Sponsor
Qilu Pharmaceutical Co., Ltd.
Enrollment target
~808 participants
Started
January 2025
Primary completion
December 2026
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in June 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Jinming Yu, PhD
Qilu Pharmaceutical Co., Ltd.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.